Comparative Pharmacology
Head-to-head clinical analysis: DORAL versus MIDAZOLAM HYDROCHLORIDE AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORAL versus MIDAZOLAM HYDROCHLORIDE AUTOINJECTOR.
DORAL vs MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABAA receptor positive allosteric modulator; enhances the inhibitory effects of GABA by binding to benzodiazepine receptors, increasing chloride channel opening frequency.
Midazolam is a short-acting benzodiazepine that potentiates GABA-A receptor activity by binding to the benzodiazepine site, enhancing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, amnestic, anticonvulsant, and muscle relaxant effects.
15-30 mg orally at bedtime, maximum 60 mg/day.
10 mg intramuscularly once via autoinjector for acute seizure control.
None Documented
None Documented
Terminal elimination half-life: 40-120 hours (long-acting benzodiazepine). Accumulation occurs with repeated dosing, especially in elderly or hepatic impairment.
Terminal elimination half-life is 1.8–6.4 hours (mean ~3 hours) in healthy adults; prolonged in elderly, obese, hepatic impairment (up to 15–20 hours), and critical illness.
Renal (primarily as metabolites; <1% unchanged). Biliary/fecal: minor.
Renal excretion of metabolites (glucuronide conjugates) accounts for approximately 90% of elimination; less than 1% excreted unchanged; minimal fecal excretion (< 5%).
Category C
Category D/X
Benzodiazepine
Benzodiazepine